Quick Answer
Eledon Pharmaceuticals, Inc. reported Net Income Loss of -$45.62 million for the year ending 2025.
- Eledon Pharmaceuticals, Inc. showed a decrease of -26.1% in Net Income Loss from 2024 to 2025.
- This data is from Eledon Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$2.39 million | Q2 2013: -$4.45 million | Q3 2013: -$3.37 million | Q4 2013: -$5.53 million | Q1 2014: -$4.85 million | Q2 2014: -$5.85 million | Q3 2014: -$6.39 million | Q4 2014: -$6.21 million | Q1 2015: -$13.26 million | Q2 2015: -$8.96 million | Q3 2015: -$11.85 million | Q4 2015: -$11.02 million | Q1 2016: -$11.43 million | Q2 2016: -$1.00 million | Q3 2016: -$2.04 million | Q4 2016: -$3.74 million | Q1 2017: -$1.37 million | Q2 2017: -$6.66 million | Q3 2017: -$2.97 million | Q1 2018: -$2.81 million | Q2 2018: -$3.19 million | Q3 2018: -$3.50 million | Q1 2019: -$4.88 million | Q2 2019: -$4.09 million | Q3 2019: -$2.89 million | Q1 2020: -$8.18 million | Q2 2020: -$2.59 million | Q3 2020: -$6.14 million | Q1 2021: -$8.50 million | Q2 2021: -$7.38 million | Q3 2021: -$9.82 million | Q1 2022: -$9.86 million | Q2 2022: -$9.25 million | Q3 2022: -$10.47 million | Q1 2023: -$10.77 million | Q2 2023: -$65.76 million | Q3 2023: -$9.91 million | Q1 2024: -$23.63 million | Q2 2024: -$44.91 million | Q3 2024: $76.97 million | Q1 2025: -$6.50 million | Q2 2025: -$11.22 million | Q3 2025: -$17.46 million.
- Over the full 14 years of available data (2012 to 2025), Eledon Pharmaceuticals, Inc.'s Net Income Loss has declined by 372.8%.
- Historical annual values: Fiscal year 2025: -$45.62 million | Fiscal year 2024: -$36.18 million | Fiscal year 2023: -$116.54 million | Fiscal year 2022: -$87.97 million | Fiscal year 2021: -$34.51 million | Fiscal year 2020: -$22.81 million | Fiscal year 2019: -$16.01 million | Fiscal year 2018: -$14.07 million | Fiscal year 2017: -$13.12 million | Fiscal year 2016: -$5.66 million | Fiscal year 2015: -$45.09 million | Fiscal year 2014: -$23.30 million | Fiscal year 2013: -$15.73 million | Fiscal year 2012: -$9.65 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: